In a groundbreaking step for regenerative medicine, Japanese researchers launched the world's first human clinical trials for a drug designed to stimulate natural tooth regrowth in 2024, with trials ongoing into 2025—potentially transforming dentistry for millions suffering from tooth loss.
Led by Dr. Katsu Takahashi at the Medical Research Institute Kitano Hospital in Osaka and Toregem BioPharma, the drug (TRG035) targets the USAG-1 protein, which suppresses tooth development. By neutralizing USAG-1 with an antibody, the treatment reactivates dormant tooth buds—allowing a potential "third set" of teeth to grow.
Animal studies in mice and ferrets showed successful new tooth formation without side effects, paving the way for human testing.
This innovation could end reliance on artificial solutions, restoring natural smiles and function. While early, the trials mark a hopeful milestone in making tooth regrowth a reality.
